Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003018 · ClinicalTrials.gov registry record · Phase 2
S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT00003018: Completed Phase 2 study, sponsored by SWOG Cancer Research Network.
NCT00003018 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 54 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003018, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed.
Interventions
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG dipyridamole
- DRUG mitomycin C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 1997-09 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
What the finished NCT00003018 record still lists
NCT00003018 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 4 interventions - of which fluorouracil is the first listed.
NCT00003018 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003018 about?
NCT00003018 is a clinical study titled "S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase II trial to study the ef...
What is the current status of trial NCT00003018?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 1997-09. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00003018?
The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), dipyridamole (DRUG), mitomycin C (DRUG).
Who is sponsoring clinical trial NCT00003018?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003018's enrollment target sits among peer trials
54 1160th of 2000 higher than 830 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia